Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.

Abstract excerpt

Kinetics-based dose targeting is often conducted in hematopoietic cell transplant (HCT) patients conditioned with intravenous (IV) or oral busulfan to lower rates of rejection, nonrelapse mortality, and relapse. Using the candidate gene approach, the authors evaluated whether busulfan clearance was associated with polymorphisms in the genes regulating the predominant metabolizing enzymes involved in busulfan...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Administration, Oral
• Share to Adolescent